The design of a constitutively active form of the C-terminal kinase domain of the p90 ribosomal S6 kinase 2 (RSK2) is described, and this is based on a phosphomimetic mutation… Click to show full abstract
The design of a constitutively active form of the C-terminal kinase domain of the p90 ribosomal S6 kinase 2 (RSK2) is described, and this is based on a phosphomimetic mutation and a C-terminal truncation, yielding a high kinase activity. The p90 ribosomal S6 kinases (RSKs) contain two distinct catalytic kinase domains, the N-terminal and C-terminal kinase domains (NTKD and CTKD, respectively). The activation of CTKD is regulated by phosphorylation by extracellular signal–regulated kinase (ERK1/2) and an autoinhibitory αL helix. Through a mutational series in vitro of the RSK CTKDs, we found a complex mechanism lifting autoinhibition that led us to design constitutively active RSK CTKDs. These are based on a phosphomimetic mutation and a C-terminal truncation (e.g., RSK2 T577E D694*) where a high activity in absence of ERK phosphorylation is obtained. Using these constructs, we characterize IC50 values of ATP-competitive inhibitors and provide a setup for determining specificity constants (kinact/Ki) of covalent CTKD inhibitors.
               
Click one of the above tabs to view related content.